Clinical Trials on L-DOPA-Induced Dyskinesia in New Zealand

Total 26 results

Yale University
UCB Pharma

Completed

Levetiracetam Treatment of Tardive Dyskinesia

Tardive Dyskinesia

United States
iRxReminder
National Institute of Mental Health (NIMH)

Recruiting

Remote Monitoring and Detecting of Tardive Dyskinesia for Improving Patient Outcomes

Tardive Dyskinesia

United States
Northwell Health

Completed

The Assessment of Movement Disorders Utilizing Live Two-Way Video

Tardive Dyskinesia

United States
Auspex Pharmaceuticals, Inc.

Completed

Aim to Reduce Movements in Tardive Dyskinesia (ARM-TD)

Tardive Dyskinesia

United States, Poland, Czechia, Slovakia
Neurocrine Biosciences

Completed

Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia (Kinect 4)

Tardive Dyskinesia

United States, Canada, Puerto Rico
Auspex Pharmaceuticals, Inc.

Completed

Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD)

Tardive Dyskinesia

United States, Czechia, Germany, Hungary, Poland, Slovakia
Neurocrine Biosciences

Completed

Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia

Tardive Dyskinesia

United States
Auspex Pharmaceuticals, Inc.

Completed

Reducing Involuntary Movements in Participants With Tardive Dyskinesia (RIM-TD)

Tardive Dyskinesia

United States, Czechia, Germany, Hungary, Poland, Slovakia
Neurocrine Biosciences

Completed

Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia

Tardive Dyskinesia (TD)

United States, Puerto Rico
Neurocrine Biosciences
Evidera

Unknown

Real-World Evaluation Screening Study and Registry of Dyskinesia in Patients Taking Antipsychotic Agents (RE-Kinect)

Tardive Dyskinesia

United States
Neurocrine Biosciences

Completed

A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia (KINECT 3)

Tardive Dyskinesia

United States, Canada, Puerto Rico
Novartis Pharmaceuticals

Completed

Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

Dyskinesias | Drug-induced

United States, France, Germany, Italy
Neurocrine Biosciences

Completed

NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder (KINECT Study)

Tardive Dyskinesia

United States, Puerto Rico
Addex Pharma S.A.

Recruiting

Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy

Parkinson Disease | Dyskinesias | Dyskinesia, Drug-Induced

United States
Adamas Pharmaceuticals, Inc.

Completed

Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study) (EASED)

Parkinson's Disease | Dyskinesia | Levodopa Induced Dyskinesia

United States
Addex Pharma S.A.

Recruiting

Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy

Parkinson Disease | Dyskinesias | Dyskinesia, Drug-Induced

United States
Adamas Pharmaceuticals, Inc.

Terminated

Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID (ALLAY-LID-II)

Parkinson's Disease | Levodopa Induced Dyskinesia (LID)

France, Germany, Canada, United States, Spain
Adamas Pharmaceuticals, Inc.

Terminated

Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID. (ALLAY-LID-I)

Parkinson's Disease | Levodopa Induced Dyskinesias (LID)

France, Spain, Germany, Canada, United States
Adamas Pharmaceuticals, Inc.

Completed

ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study) (EASE LID)

Parkinson's Disease | Dyskinesia | Levodopa Induced Dyskinesia (LID)

United States, Canada
Neurocrine Biosciences

Recruiting

Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia

Schizophrenia | Schizoaffective Disorder | Bipolar Disorder | Tardive Dyskinesia | Major Depressive Disorder

United States
Adamas Pharmaceuticals, Inc.

Completed

Open-Label Safety Study of ADS-5102 in PD Patients With LID

Parkinson's Disease (PD) | Dyskinesia | Levodopa Induced Dyskinesia (LID)

France, Spain, United States, Canada, Germany, Austria
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Completed

Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder

Marijuana Abuse | Attention Deficit Disorder With Hyperactivity

United States
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Completed

Atomoxetine for Treating Cocaine Abuse in Adults With Attention Deficit Hyperactivity Disorder (ADHD) (Atom)

Cocaine-Related Disorders | Attention Deficit Disorder With Hyperactivity

United States
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Completed

Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder (MJ-ADHD)

Attention-deficit/Hyperactivity Disorder | Cannabis Use Disorder

United States
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Completed

Study of Adderall-XR for the Treatment of Adult Attention Deficit Hyperactivity Disorder and Cocaine Dependence (CAMP)

Cocaine Dependence | Adult Attention Deficit Hyperactivity Disorder

United States
All India Institute of Medical Sciences, New Delhi

Unknown

Sleep Quality in Pregnancy and Its Impact on Pregnancy Outcomes

Obstructive Sleep Apnea | Infant, Very Low Birth Weight | Pregnancy Induced Hypertension | High-Risk Pregnancy | Restless Leg Syndrome

India

Clinical Trials on L-DOPA-Induced Dyskinesia in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations